NYSE$COR

Cencora Inc · Q2 2023 earnings

Q2 2023 earnings · · Investor relations

Briefing

AmerisourceBergen reported strong financial results for Q2 2023, with revenue increasing by 9.9% year-over-year and adjusted diluted EPS rising by 8.7%.

AmerisourceBergen Corporation's Q2 2023 earnings showcased a robust 9.9% increase in revenue, reaching $63.5 billion. Adjusted diluted EPS grew by 8.7% to $3.50, reflecting the company's strong financial performance and strategic execution. The company raised its full-year financial outlook, demonstrating the value of its pharmaceutical-centric strategy and key strategic partnerships.

  • Revenue increased by 9.9% year-over-year to $63.5 billion.
  • GAAP diluted EPS was $2.13, while adjusted diluted EPS increased by 8.7% to $3.50.
  • U.S. Healthcare Solutions revenue increased by 11.3% year-over-year.
  • The company raised its adjusted diluted EPS guidance range for fiscal year 2023 to $11.70 to $11.90.

Headline financials

Total Revenue

$63.5B

Previous: $57.7B+9.9%
EPS (adj)

$3.50

Previous: $3.22+8.7%
Effective Tax Rate

16.4%

Previous: 23.7%-30.8%
Adj. Effective Tax Rate

19.0%

Previous: 21.0%-9.5%
Capital Expenditures

-$179M

Previous: -$209M+14.7%
Free Cash Flow

$257M

Previous: $339M-24.2%
Net Income

$435M

Previous: $548M-20.5%
Operating Income

$561M

Previous: $780M-28.2%
Gross Profit

$2.3B

Previous: $2.24B+2.7%
Cash & Equivalents

$1.54B

Previous: $2.96B-48.0%
Total Assets

$58.8B

Previous: $57.3B+2.5%
Stock-Based Comp

$23.5M

Previous: $19.6M+19.6%

Revenue & EPS history

Cencora · Revenue · Quarterly

$63.5B

Q2 2023+9.9%vs Q2 2022
Beat estimate in 8 of 15 quarters(53%)
ActualEstimate

Forward guidance

AmerisourceBergen is updating its fiscal year 2023 financial guidance to primarily reflect stronger core growth in the U.S. Healthcare Solutions segment. The Company now expects revenue growth to be in the range of 6 to 8 percent and Adjusted Diluted Earnings Per Share to be in the range of $11.70 to $11.90.

Tailwinds

  • Revenue growth to be in the range of 6 to 8 percent, up from the previous range of 5 to 7 percent.
  • U.S. Healthcare Solutions revenue growth to be in the range of 7 to 8 percent, narrowed from the previous range of 6 to 8 percent.
  • International Healthcare Solutions revenue to be in the range of a 3 percent decline to flat, up from the previous range of a 1 to 5 percent decline.
  • Adjusted Diluted Earnings Per Share to be in the range of $11.70 to $11.90, representing growth of 6 to 8 percent, raised from the previous range of $11.50 to $11.75.
  • Adjusted consolidated operating income growth to be in the range of 2 to 4 percent, up from the previous range of 0 to 3 percent.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2023

Historical avgQ2 2023

-0.1%

Avg return

Earnings day

+0.3%

Avg return

5 days after

+1.4%

Avg return

30 days after

48%

35 / 73 earnings

Positive

+7.8%

Q2 2019

Best reaction

-18.4%

Q2 2026

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q2 2026-18.4%-16.6%-10.1%
Q1 2026-5.9%+0.4%-0.9%
Q4 2025+2.9%+5.8%-1.4%
Q3 2025-2.9%-0.6%+0.1%
Q2 2025+4.6%-4.3%-0.6%
Q1 2025+0.7%-2.1%+1.2%
Q4 2024+5.9%+6.5%+4.0%
Q3 2024+5.8%+4.4%+3.7%
Q2 2024-6.0%-6.3%-5.2%
Q1 2024+7.4%+6.2%+7.5%
Q4 2023+4.2%+4.7%+9.0%
Q3 2023+1.2%-1.3%-7.5%
Q2 2023+0.1%+0.7%+3.5%
Q1 2023-6.2%-8.6%-7.6%
Q4 2022+4.4%+3.1%+12.4%
Q3 2022-2.5%-1.5%+3.4%
Q2 2022+2.9%+4.4%-2.5%
Q1 2022+0.2%+1.3%+7.0%
Q4 2021-0.6%-2.8%-9.0%
Q3 2021-1.5%-2.8%+1.2%
Q2 2021-6.5%-2.1%-7.1%
Q1 2021+3.9%+1.8%-0.7%
Q4 2020-1.0%+4.8%-1.9%
Q3 2020-3.0%-1.6%-7.7%
Q2 2020+3.0%+3.6%+15.8%
Q1 2020-4.8%-2.0%-6.2%
Q4 2019+1.6%+1.0%+4.2%
Q3 2019+3.8%-3.5%-5.6%
Q2 2019+7.8%+5.5%+6.1%
Q1 2019+6.7%+9.2%+5.7%
Q4 2018-2.3%+0.3%-2.9%
Q3 2018+1.9%+5.0%+13.2%
Q2 2018-4.3%-5.1%-6.6%
Q1 2018+2.5%-2.9%+4.7%
Q4 2017-2.4%-2.2%+10.9%
Q3 2017-11.4%-12.0%-12.1%
Q2 2017+3.9%+5.9%+13.2%
Q1 2017+6.0%+6.8%+9.9%
Q4 2016+3.6%+3.1%+12.9%
Q3 2016+5.1%+4.5%+1.9%
Q2 2016-9.2%
Q1 2016-3.7%
Q4 2015-1.0%
Q3 2015-5.4%
Q2 2015+1.9%
Q1 2015+0.4%
Q4 2014+7.1%
Q3 2014+3.7%
Q2 2014-3.1%
Q1 2014-4.3%
Q4 2013+1.8%
Q3 2013-0.0%
Q2 2013-4.6%
Q1 2013-5.1%
Q4 2012-0.6%
Q3 2012+2.7%
Q2 2012-1.2%
Q1 2012+2.4%
Q4 2011-1.0%
Q3 2011-0.5%
Q2 2011+2.9%
Q1 2011+0.5%
Q4 2010-0.5%
Q3 2010-0.7%
Q2 2010+1.0%
Q1 2009-1.7%
Q1 2010+1.2%
Q4 2009-0.6%
Q2 2009-0.6%
Q4 2007-0.6%
Q3 2008-0.5%
Q3 2009-0.5%
Q4 2008-0.5%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro